Buckley Wealth Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, Holdings Channel reports. The fund acquired 40,954 shares of the company’s stock, valued at approximately $5,722,000. Johnson & Johnson accounts for 2.9% of Buckley Wealth Management LLC’s investment portfolio, making the stock its 8th biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Enterprise Financial Services Corp boosted its holdings in Johnson & Johnson by 2.4% in the 4th quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock valued at $2,106,000 after purchasing an additional 358 shares during the period. Welch Investments LLC boosted its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock valued at $5,027,000 after purchasing an additional 373 shares during the period. YHB Investment Advisors Inc. boosted its holdings in Johnson & Johnson by 0.5% in the 4th quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock valued at $10,693,000 after purchasing an additional 381 shares during the period. Franklin Parlapiano Turner & Welch LLC boosted its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock valued at $5,363,000 after purchasing an additional 382 shares during the period. Finally, Regent Investment Management LLC boosted its holdings in Johnson & Johnson by 0.8% in the 4th quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock valued at $6,591,000 after purchasing an additional 385 shares during the period. 66.16% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson opened at $119.62 on Friday, Marketbeat Ratings reports. The company has a market cap of $320.34 billion, a P/E ratio of 16.39, a P/E/G ratio of 1.83 and a beta of 0.74. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.83 EPS. research analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 3.01%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Friday, May 25th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

A number of analysts have recently weighed in on JNJ shares. Vetr raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating and set a $152.28 price target for the company in a report on Monday, February 5th. Citigroup cut their price target on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. Jefferies Group set a $165.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. TheStreet downgraded shares of Johnson & Johnson from an “a” rating to a “c+” rating in a report on Monday, March 26th. Finally, Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 price target for the company in a report on Wednesday, March 28th. Six investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $142.23.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.